Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 13

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 8
Chunk 13
---
 Under the 2019 Plan, the RSU term is not to exceed 10 years. The fair value is based on the 5-day VWAP of the Company’s Common Shares up to the date of grant.

14

The following is a summary of changes in the status of RSUs from October 1, 2024 through June 30, 2025:

			Number of RSU (#)

			Weighted Average Grant Date Fair Value

			Nine Months Ended June 30, 2025

			Balance - September 30, 2024

			63,204

			$
			5.10

			Granted

			1,207,856

			2.00

			Exercised

			(2,486
			)

			5.60

			Balance - June 30, 2025

			1,268,574

			$
			2.15

			Nine Months Ended June 30, 2024

			Balance - September 30, 2023

			33,045

			$
			5.60

			Granted

			19,772

			4.52

			Balance - June 30, 2024

			52,817

			$
			5.20

The following table summarizes information about the RSUs under the 2019 Plan outstanding and exercisable at June 30, 2025:

			Number of RSU (#) 

			Exercisable at
			June 30, 2025 (#) 

			Expiry Date

			Fully-vested RSUs

			117,967

			117,967

			August 2033 - June 2035

			Vesting in the next 12 months

			262,090

			21,828

			May 2035

			Vesting from 13–24 months

			403,062

			22,364

			May 2035

			Vesting in 24 months or greater

			485,455

			14,087

			May 2035

			1,268,574

			176,246

			-

The Company has granted RSUs with varying vesting schedules. Certain RSU’s vest immediately upon the grant date, while others vest over